Currently, numerous irreversible KDM1A (LSD1) inhibitors have been identified and among them TCP, ORY-1001 and SP2509 are now evaluated in clinical trials as potential cancer treatments (Fang et al., 2019; Liang et al., 2020). Here, KDM1A is linked to cancer.